[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arterial-occlusive-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arterial-occlusive-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,91,117,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641226","phase-3-evaluating-bu-yang-huanwu-decoction-for-early-diabetic-vascular-disease-100641226",false,"NCT07658807","Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease","Evidence-Based Evaluation and New Drug Translation Research of Early Intervention With the Classic Traditional Chinese Medicine Formula Bu Yang Huanwu Decoction for Preventing and Treating Diabetic Lower Extremity Vascular Disease","Inclusion Criteria:\n\n1. Aged 18 to 70 years (inclusive), male or female.\n2. Diagnosed with diabetes mellitus according to the Chinese Diabetes Society (2024) Guidelines.\n3. Glycated hemoglobin (HbA1c) \\\u003C 12%, with recent fasting blood glucose \\\u003C 7.0 mmol\u002FL OR postprandial blood glucose \\\u003C 10.0 mmol\u002FL, and triglycerides \\\u003C 1.7 mmol\u002FL.\n4. Diagnosed with LEAD, meeting the following criteria:\n\n   Rutherford Classification 2, 3, or 4.\n\n   Resting ABI ≤ 0.90, OR for patients with exertional symptoms and resting ABI \\> 0.90, a post-exercise treadmill test showing an ABI decrease of ≥15%.\n\n   Evidence of lower limb arterial stenosis or occlusion confirmed by duplex ultrasound, CTA, MRA, or DSA.\n5. TCM Pattern Diagnosis: Must conform to the TCM syndrome of Qi Deficiency and Blood Stasis, as defined by the study's TCM diagnostic criteria (referencing \"Practical Diagnostic Criteria for Blood Stasis Syndrome\" and \"Integrated Chinese and Western Medicine Peripheral Vascular Disease\"):\n\n   Main Symptom: Lower limb weakness, or feeling of heaviness\u002Fdiscomfort after prolonged walking.\n\n   Secondary Symptoms: Shortness of breath\u002Flassitude in speaking; dry mouth with desire to drink; scaly skin.\n\n   Tongue \\& Pulse: Tongue with teeth marks, pale-purple with petechiae\u002Fecchymosis; thin and choppy pulse.\n\n   (Diagnosis confirmed by meeting 1 main symptom OR 2 secondary symptoms, assessed by a qualified TCM practitioner.)\n6. Voluntarily signs the Informed Consent Form (ICF) and is willing and able to comply with all study procedures and visits.\n\nExclusion Criteria:\n\n1. Known bleeding disorders or history of intracranial hemorrhage.\n2. Current use of anticoagulants (e.g., warfarin, dabigatran, factor Xa inhibitors).\n3. Presence of active infection.\n4. Severe cardiac abnormalities on resting ECG (e.g., heart failure, ventricular tachycardia, ventricular fibrillation, multifocal ventricular contractions, prolonged corrected QT interval).\n5. History of acute coronary syndrome ≤ 12 months requiring dual antiplatelet therapy.\n6. Chronic liver disease (Child-Turcote-Pugh score ≥5) or chronic kidney disease stages 4-5 (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n7. History of malignancy (except cured basal cell carcinoma).\n8. Moderate to severe anemia, polycythemia vera, or any hyperviscosity syndrome.\n9. Planned lower limb revascularization or amputation.\n10. Concurrent or planned use of medicinal products containing Veratrum species.\n11. Pregnant or lactating women, or women of childbearing potential not using highly effective contraception.\n12. Known allergy or hypersensitivity to any component of the study medication (Qilong Capsules, aspirin).\n13. Patients with psychiatric disorders or judged to be uncooperative.\n14. Currently participating in another drug clinical trial or using therapies with similar purported effects.\n15. Any other condition deemed by the investigator to make the participant unsuitable for the trial.","ALL","18 Years","70 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to learn if adding a Traditional Chinese Medicine formula, Bu Yang Huanwu Decoction (specifically the capsule form called Hua Yu Wan Capsule), to standard treatment can help prevent leg pain at rest or foot ulcers in people with diabetic lower extremity vascular disease. The main questions it aims to answer are:\n\nDoes adding Hua Yu Wan Capsule to standard treatment lower the chance of developing leg pain at rest or foot ulcers after one year, compared to standard treatment alone?\n\nIs the treatment combination safe for participants?\n\nResearchers will compare two groups:\n\nGroup 1 (Experimental): Standard treatment (including aspirin, and medicines for blood sugar and cholesterol control) plus Hua Yu Wan Capsule.\n\nGroup 2 (Control): Standard treatment alone.\n\nParticipants in this study will:\n\nBe adults aged 18 to 70 years with diabetes and early to moderate lower extremity vascular disease (confirmed by tests like the Ankle-Brachial Index or ABI).\n\nBe randomly assigned to one of the two treatment groups.\n\nTake their assigned treatment for 6 months.\n\nAttend clinic visits at 1, 3 and 6 months during treatment, and again at 6 and 12 months after treatment ends for check-ups and tests.",[27,28,29],"Peripheral Arterial Disease","Diabetic Angiopathies","Arterial Occlusive Diseases",[27,31,32,33],"Ischemia","Medicine, Chinese Traditional","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":21},"2026-06",{"date":42,"type":21},"2029-01",{"name":44,"class":45},"Xuanwu Hospital, Beijing","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":76,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":46},"100612800","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-rms-system-in-subjects-with-coronary-artery-lesions-100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)","80 Years",{"count":57,"type":21},1859,[59],"NA","The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[62,63,64,65,29,66,67,68,69,70,71,72,73,74,75],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Vascular Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Angina Pectoris",[77,78,79,80],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","RECRUITING",{"date":83,"type":38},"2026-06-17",{"date":85,"type":38},"2026-06-11",{"date":87,"type":21},"2033-06",{"name":89,"class":90},"Teleflex","INDUSTRY",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100614975","a-prospective-multicenter-randomized-controlled-trial-to-investigate-the-value-of-coronary-ct-angiography-in-the-understanding-and-management-of-coronary-calcium-the-optimal-trial-100614975","NCT07286578","A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)","A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium","Inclusion Criteria:\n\n* The subject must be at least 18 years of age and younger than 85 years old\n* Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia (ischemia in the absence of chest pain or other anginal equivalents), unstable angina, or acute myocardial infarction) suitable for PCI. Patients with a clinical indication for revascularization presenting with stable coronary artery disease or stabilized acute coronary syndrome defined as follows unstable angina (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC), patients with NSTEMI without high-risk features such as recurrence of chest pain, ST-segment depression\\>1mm in ≥6 leads plus STsegment elevation in aVR, life-threatening arrhythmias, mechanical complications of MI, resuscitated cardiac arrest, GRACE risk score\\>140.\n* All target vessels must have reference vessel diameter (visually assessed by CCTA) ≥ 2.5 mm\n* Subject must provide written informed consent before any study-related procedure\n\nExclusion Criteria:\n\n* STEMI as the clinical presentation.\n* Uncontrolled or recurrent ventricular tachycardia.\n* Hemodynamic instability.\n* Hemodialysis or peritoneal dialysis.\n* Left main coronary artery stenosis \\> 50%\n* Atrial fibrillation, flutter, or arrhythmias during CT acquisition.\n* Previous PCI in the target vessel or CABG.\n* BMI ≥ 40 kg\u002Fm2\n* Insufficient CT quality assessed by the Core lab.\n* Comorbidity with life expectancy ≤ 2 years.\n* Planned major cardiac or non-cardiac surgery within 24 months after the index procedure Note: Major surgery is any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: Minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.\n* The subject has received a solid organ transplant that is functioning or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.\n* The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.\n* The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest\u002Fmediastinum.\n* Subject has a platelet count \\\u003C100,000 cells\u002Fmm3 or \\>700,000 cells\u002Fmm3.\n* The subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.\n* The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, or any prior intracranial bleed, or any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy \\\u003C2 years for any non-cardiac cause.\n* Subject is currently participating in another investigational drug or device clinical study.\n* Pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.\n* Unable to provide written informed consent (IC).","85 Years",{"count":100,"type":21},700,[59],"The OPTIMAL randomized clinical trial has been designed to compare two imaging strategies and to test the hypothesis that a calcium modification strategy informed by coronary CT angiography (CCTA) will improve procedural efficiency and effectiveness compared with the current standard of care (IVUS-guided PCI) while achieving similar clinical outcomes in patients with hemodynamically significant calcified coronary artery disease.",[64,73,63,65,29,66,72],[105,106],"IVUS","CT","2026-02-09",{"date":109,"type":38},"2026-02-10",{"date":111,"type":38},"2025-12-22",{"date":113,"type":21},"2030-01-01",{"name":115,"class":45},"Fundación EPIC",13,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":147,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":46},"100557242","single-vs-dual-antiplatelet-therapy-in-elderly-or-hbr-patients-undergoing-percutaneous-intervention-with-dcb-piccoleto-iv-epic-38-100557242","NCT06535568","Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","International, Multicenter, Investigator-driven Randomized Clinical Trial to Assess the Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (PICCOLETO IV-EPIC 38)","PIV-EPIC","Inclusion Criteria:\n\nMale and female patients who meet the following criteria:\n\n* Age ≥ 75 years or age ≥ 18 years at high bleeding risk;\n* Successful PCI with Essential Pro DCB just performed, in 1, 2 or 3 coronary vessels;\n* Stable or unstable coronary syndromes;\n* De novo coronary lesions in vessels with diameter ≥2.0 and ≤4.0 mm (visual estimation);\n* Informed consent to participate in the study given by the patient or impartial witness.\n\nExclusion Criteria:\n\n* Stent implantation during index or recent (\\\u003C6 months) procedure;\n* Known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, paclitaxel or contrast media, or any of their excipient which cannot be adequately pre-medicated;\n* Pregnancy at the time of hospitalization;\n* Patients participating in another clinical study in which an investigational drug or device was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer;\n* ST-elevation myocardial infarction;\n* Life expectancy \\\u003C12 months;\n* Left ventricular ejection fraction \\\u003C30%;\n* Visible thrombus at lesion site;\n* Target lesion\u002Fvessel with any of the following characteristics:\n\n  * severe and\u002For \\>270° calcification of the target vessel, also proximal to the lesion (intravascular imaging not mandatory);\n  * left main stem stenosis \\>50%;\n  * target lesion is in the left main stem;\n  * chronic total occlusion with anticipated necessity of retrograde approach;\n  * lesion is in a bypass graft.\n* History of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines (NSAIDs);\n* History of gastrointestinal perforation, ulceration, or bleeding (peptic ulcer bleeding-PUBs) related to previous use of NSAIDs or anticoagulant medications, or intracranial hemorrhage;\n* Acute gastrointestinal ulcers;\n* Hemorrhagic diathesis (including known bleeding disorders or ongoing active bleeding);\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin);\n* Severe hepatic impairment (Child-Pugh C), with elevated liver enzymes (ALT\u002FAST \\> 2 x ULN or total bilirubin \\>1.5 x ULN);\n* Severe cardiac failure (NYHA grade III or IV);\n* Combination with methotrexate at doses of 15 mg\u002Fweek or more;\n* Patients with baseline neutrophil counts \\\u003C 1500 cells\u002Fmm³;\n* Breastfeeding women;\n* Full-blown thyrotoxicosis;\n* Patients with a very high risk of thrombosis.",{"count":126,"type":21},576,[59],"This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients undergoing percutaneous coronary intervention (PCI) with the latest generation drug-coated balloon (DCB). The study includes patients with stable or unstable coronary syndromes and aims to assess rates of ischemic and bleeding adverse events.",[62,63,64,73,130,29,66,72,74,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146],"Atherosclerosis","Coronary Stenosis","Molecular Mechanisms of Pharmacological Action","Enzyme Inhibitors","MTOR Inhibitors","Protein Kinase Inhibitors","Physiological Effects of Drugs","Immunosuppressive Agents","Antineoplastic Agents","High Bleeding Risk","Single Antiplatelet Therapy","Dual Antiplatelet Therapy","Cyclooxygenase Inhibitors","P2Y12 Inhibitor","Platelet Aggregation Inhibitors","Aspirin","Clopidogrel",[148,149,150,151,152,153,154,155,156,157],"DCB","Angioplasty","Paclitaxel","Antiplatelet treatment","Single antiplatelet therapy (SAPT)","Dual antiplatelet therapy (DAPT)","High bleeding risk (HBR)","MACE","Native CAD","stable or unstable coronary syndromes","2026-01-21",{"date":160,"type":38},"2026-01-22",{"date":162,"type":38},"2026-01-10",{"date":164,"type":21},"2028-02-20",{"name":166,"class":45},"Fondazione Ricerca e Innovazione Cardiovascolare ETS",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},"100510723","results-of-the-use-of-two-stentrievers-simultaneosly-compared-with-one-as-a-primary-treatment-in-acute-ischemic-stroke-100510723","NCT05930145","Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke","A Randomized Study Comparing the Effectiveness and Security of the Use of Two Stentrievers Simultaneously Versus One Stentriever as a Primary Treatment in Acute Ischemic Stroke Patients.","DIVERSO","Inclusion Criteria:\n\n* A new disabling focal neurological deficit compatible with acute cerebral ischemia.\n* Any age. Informed consent obtained from the patient or representative.\n* NIHSS score ≥ 6.\n* Pre-existing functional clinical status less than or equal to 2 according to the mRS clinical scale.\n* Maximum time of 24 hours from symptom onset to arterial puncture. • TICI 0-1 in the diagnosed TICA (terminal internal carotid artery) , MCA (middle cerebral artery), and BA( basilar artery confirmed by angioCT and angiography).\n* ASPECTs score on baseline CT greater than or equal to 6.\n* In cases where it is indicated, prior intravenous fibrinolysis will be administered according to the protocols of each center.\n\nExclusion Criteria:\n\n* Those described in the usual protocols for mechanical thrombectomy of each hospital.\n* Pre-existing functional clinical status greater than 2 according to the mRS clinical scale\n* Patients with tandem lesions of dissection or arteriosclerotic origin located in the extracranial internal carotid artery.\n* Initiation of treatment with a different technique than the one described.\n* Inability to use a proximal balloon guide catheter.\n* Use of aspiration catheter.\n* Intracranial atherosclerotic plaque as the cause of occlusion.\n* Advanced or terminal disease with a life expectancy of less than 6 months.\n* Patient who is participating in another study that may affect this one.\n* ASPECTS score less than or equal to 6 on baseline CT.\n* Evidence of significant hemorrhage or mass effect with midline shift on baseline CT.\n* Patients with occlusions in multiple vascular territories.\n* Evidence of intracranial tumor (except for small meningiomas)",{"count":176,"type":21},200,[59],"Several studies have demonstrated that simultaneous treatment with two stentrievers (STs) as rescue treatment is very effective, with high recanalization rates even in this group of patients where other revascularization techniques have failed. There has been no observed increase in hemorrhagic complications. Recently, a prospective study has been published where treatment with two ST has been shown to be effective and safe if used as a first-choice treatment (not as rescue) with a successful recanalization rate (eTICI 2c\u002F3) after the first pass of 69%. These results have been reinforced after the publication of a randomized study that confirms, in vitro, the superiority of using two ST over one.",[180,181,29],"Stroke","Thrombectomy",[180,183,181],"Double Stentriever","2025-07-24",{"date":186,"type":38},"2025-07-28",{"date":188,"type":38},"2025-03-14",{"date":190,"type":21},"2026-10-01",{"name":115,"class":45},4]